MedTrace Logo

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry

NCT05430971 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2026-02-17

No results posted yet for this study

Summary

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is a very rare hematologic malignancy. Despite recent advances, at present there is no consensus on the optimal treatment of BPDCN. The optimal therapy of disease remains to be determined, and due to the rarity of cases, there is a need for international collaboration to collect data on BPDCN clinical presentations, diagnostics, treatment regimens and outcomes. Therefore, the objectives of this study are: (1) to build a large database of patients with BPDCN, (2) to investigate the characteristics and outcome of the disease with different treatment regimens, (3) to evaluate prognostic factors, and (4) to generate data-based prospective treatment recommendations.

Conditions

  • Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Sponsors & Collaborators

  • Immune Oncology Research Institute

    lead OTHER

Principal Investigators

  • Astghik Voskanyan, MD · Immune Oncology Research Institute, Yerevan, Armenia

  • Gevorg Tamamyan, MD, PhD, DSc · Immune Oncology Research Institute, Yerevan, Armenia

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-01
Primary Completion
2032-07-31
Completion
2032-07-31

Countries

  • United States
  • Armenia
  • Canada
  • Cyprus
  • Egypt
  • Georgia
  • India
  • Iraq
  • Italy
  • Kuwait
  • Romania
  • Taiwan
  • Turkey (Türkiye)
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05430971 on ClinicalTrials.gov